Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 206

Results For "results"

2111 News Found

AstraZeneca-Sputnik V combination demonstrates high immunogenicity profile: RDIF
Biotech | August 20, 2021

AstraZeneca-Sputnik V combination demonstrates high immunogenicity profile: RDIF

Preliminary data from the first 20 participants in Azerbaijan show antibodies to the SARS-CoV-2 virus spike protein (S-protein) elicited in 100% of cases


Zydus Cadila receives Emergency Use Authorisation for 3-dose ZyCoV-D vaccine
Biotech | August 20, 2021

Zydus Cadila receives Emergency Use Authorisation for 3-dose ZyCoV-D vaccine

This is the world’s first Covid=19 DNA vaccine developed in partnership with DBT-BIRAC


FDA grants Emergency Use Authorization for next-generation Covid-19 assays
Digitisation | August 19, 2021

FDA grants Emergency Use Authorization for next-generation Covid-19 assays

Thermo Fisher’s kits leverage an updated design from the original TaqPath assays, targeting eight different genes across three regions of the virus that causes Covid-19


Real world data from Paraguay shows one-shot Sputnik Light vaccine has high safety and efficacy of 93.5 %
Biotech | August 18, 2021

Real world data from Paraguay shows one-shot Sputnik Light vaccine has high safety and efficacy of 93.5 %

Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik


Test At Home (TAH), offers convenient saliva-based testing for Covid-19
Drug Approval | August 18, 2021

Test At Home (TAH), offers convenient saliva-based testing for Covid-19

TAH is now undergoing regulatory clearance and final quality control procedures for the swab deployment in India, EU, Singapore, UK, US, Australia and others for COVID-19 testing


Pfizer & BioNTech submits Phase 1 data to US FDA for booster dose Covid-19
Biotech | August 17, 2021

Pfizer & BioNTech submits Phase 1 data to US FDA for booster dose Covid-19

The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.


Fortis Healthcare PAT at Rs 263.55 cr in Q1FY22
Healthcare | August 16, 2021

Fortis Healthcare PAT at Rs 263.55 cr in Q1FY22

It has initiated investments for advanced medical equipment such as Cath Labs, neuro microscopes, bone marrow transplant units at select facilities


Apollo Hospitals PAT at Rs 489.28 cr. in Q1FY22
Healthcare | August 16, 2021

Apollo Hospitals PAT at Rs 489.28 cr. in Q1FY22

The hospital chain aggressively embarks on digitisation and is e-health ready


Aurobindo Pharma buys Cronus Pharma Specialities for Rs 420 crores
News | August 13, 2021

Aurobindo Pharma buys Cronus Pharma Specialities for Rs 420 crores

The acquisition will provide it with a foothold in the US $ 48 billion global animal health market


JB Chemicals & Pharmaceuticals PAT at Rs. 118.9 cr for Q1 FY22
News | August 13, 2021

JB Chemicals & Pharmaceuticals PAT at Rs. 118.9 cr for Q1 FY22

Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21